Drug

SPU-16

Multiple Sclerosis (MS)

Drug

Central nervous system homing peptide.

  • Preclinical research.

Unmet need:

  • Global MS drugs market size projected growth to $38.9B
    by 2032, at a 7.9% CAGR.

Medical needs:

  • Directly targets damaged tissue and inflammation in spinal cord.
Previous Drug
Next Drug

Competitive advantages

  • Novel homing peptides reduce toxicity and advance
    payload of therapeutic.
Previous Drug
Next Drug

Get more information on Silo Pharma. Sign up for email alerts online.

SIGN UP